Circular Genomics and Vitazi.ai Partner to Develop AI-Powered Multimodal Alzheimer's Detection Platform
核心洞察
Circular Genomics (搜索) and Vitazi.ai (搜索) announced a strategic alliance to develop a first-in-class multimodal workflow combining AI-powered retinal imaging with circular RNA (搜索) biomarkers for early Alzheimer's disease (搜索) detection.
The collaboration addresses critical gaps in early-stage Alzheimer's diagnosis, where millions of patients are missed due to limitations in accuracy, accessibility, and cost of existing diagnostic approaches.
The two-step clinical workflow features AI-driven retinal triage in primary care settings followed by blood-based circRNA (搜索) molecular confirmation to provide pathway-level disease insight.
Circular Genomics (搜索), a precision neurology company pioneering circular RNA (搜索) (circRNA (搜索))-based molecular diagnostics, has announced a strategic alliance with Vitazi.ai (搜索), an innovator in AI-powered retinal imaging and oculomics, to jointly develop a next-generation multimodal workflow for early detection and risk stratification of Alzheimer's disease (搜索). The collaboration establishes what the companies describe as a first-in-class diagnostic architecture designed to address critical market gaps in early-stage patient identification.
Addressing Diagnostic Gaps in Alzheimer's Disease
Despite affecting millions of individuals globally, Alzheimer's disease (搜索) is often diagnosed years after symptom onset, with a significant proportion of early-stage patients missed due to limitations in accuracy, accessibility, and cost of existing diagnostic approaches. This diagnostic gap represents both a profound clinical challenge and a substantial market opportunity for scalable, accessible solutions capable of identifying patients earlier in the disease continuum.
The collaboration aims to unlock one of the most significant unmet needs in Alzheimer's disease (搜索): the systematic underdiagnosis of patients in the earliest, most treatable stages—where therapeutic intervention holds the greatest potential for clinical and economic impact.
Two-Step Multimodal Diagnostic Workflow
The partnership will combine Vitazi.ai (搜索)'s non-invasive AI-driven retinal imaging analytics with Circular Genomics (搜索)' proprietary circRNA (搜索) biomarker data through shared algorithmic and machine learning workflows. The envisioned diagnostic process introduces a two-step clinical workflow designed for scalability, accessibility, and seamless integration into existing care pathways:
Step 1: AI-Driven Retinal Triage — Non-invasive retinal imaging conducted in optometry or primary care settings to identify individuals at elevated risk, enabling broad population-level screening with minimal infrastructure requirements.
Step 2: circRNA (搜索) Molecular Confirmation — Blood-based detection of brain-derived circRNA biomarkers to confirm early disease biology and pathology, providing molecular precision and disease pathway-level insight beyond traditional protein biomarkers.
Technology Platform Advantages
Circular RNA (搜索) biomarkers are uniquely suited for neurodegenerative disease applications due to their stability, enrichment in brain tissue, and ability to cross the blood-brain barrier. Unlike single-analyte protein biomarkers, circRNAs enable a broader, pathway-level understanding of disease biology, offering the potential to better capture the complexity and heterogeneity of Alzheimer's disease (搜索)—a critical advantage for both diagnostic accuracy and therapeutic development support.
Vitazi.ai (搜索)'s oculomics platform leverages retinal imaging as a non-invasive window into systemic and neurological health, enabling optometrists and frontline clinicians to play an expanded role in preventive care and disease detection.
Leadership Perspectives
"This collaboration represents a transformative step in how we scale early Alzheimer's detection and expand the commercial and strategic reach of our circRNA (搜索) platform," said Paul Sargeant, PhD, Chief Executive Officer of Circular Genomics (搜索). "Our circRNA technology provides a systems-level view of Alzheimer's disease (搜索) biology capable of detecting molecular changes upstream of traditional protein biomarkers. Strategically, this partnership extends our platform's clinical utility, accelerates market penetration across primary care and specialty settings, and creates compelling new opportunities for pharmaceutical partnerships focused on clinical trial enrichment, patient stratification, and real-world evidence generation."
Jeremy Stueven, MD, Chief Executive Officer of Vitazi.ai (搜索), emphasized the complementary nature of the technologies: "We believe the future of disease detection lies in combining complementary data modalities that reflect different dimensions of human biology. The retina provides a unique, non-invasive lens into neurological and vascular health, while circRNA (搜索) offers deep molecular insight into disease pathways. Together, we could create a scalable, clinically meaningful solution that empowers providers to detect disease earlier and intervene more effectively delivering value across the care continuum."
Scientific Foundation
Nikolaos Mellios, MD, PhD, Chief Scientific Officer and Co-Founder of Circular Genomics (搜索), highlighted the scientific approach: "This collaboration enables the melding of orthogonal biological signals—structural and molecular—into unified predictive models of disease through joint analytical framework development. This approach represents a fundamental advancement in how we model and measure neurodegenerative disease biology, with implications that extend well beyond Alzheimer's to the broader landscape of precision neurology."
The collaboration will initially focus on the joint development of multimodal machine learning models that combine retinal imaging data with blood circRNA (搜索) biomarker profiles to deliver intelligent early AD diagnostic and disease progression risk insights. The multimodal analytical approach is engineered to enable earlier, more accurate patient identification, expand access to care across diverse healthcare settings, and support more effective deployment of emerging disease-modifying therapies.